Amparo Urios

Dr. Amparo Urios

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2011 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
Vicente FelipoVicente Felipo
Vicente Felipo
AUAmparo Urios
Amparo Urios
EMEncarna Montesinos
Encarna Montesinos
IMInmaculada Molina
Inmaculada Molina
MGMaria L. Garcia-Torres
Maria L. Garcia-Torres
CMCarmina Montoliu
Carmina Montoliu

1 March 2009 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
CMCarmina Montoliu
Carmina Montoliu
BPBlanca Piedrafita
Blanca Piedrafita
MSMiguel A. Serra
Miguel A. Serra
JOJuan A. del Olmo
Juan A. del Olmo
AUAmparo Urios
Amparo Urios
Vicente FelipoVicente Felipo
Vicente Felipo
Background and Aims Patients with liver cirrhosis may present minimal hepatic encephalopathy (MHE) that can be unveiled using specific neuropsychologic examination. Evaluation of MHE in cirrhotic patients might have prognostic value. The psychometric HE score (PHES) has been recommended as the “gold standard” in the diagnosis of MHE. It has been proposed that critical flicker frequency (CFF) analysis would be useful for easier detection of MHE. It would also be useful to have some peripheral parameter that could reflect the presence of MHE. It has been recently proposed that inflammation-associated alterations and hyperammonemia may cooperate in the induction of hepatic encephalopathy. The aim of the present work was to assess whether there is a correlation between the alterations in parameters reflecting inflammation, hyperammonemia, and the presence of MHE. Methods We have studied in 55 patients with liver cirrhosis and 26 controls the performance in the PHES battery and the CFF, ammonia, and some interleukins (ILs) as inflammatory markers. Results IL-6 and IL-18 were significantly higher (2.5-fold and 2.2-fold, respectively) in patients with MHE than in those without MHE. There were significant correlations between IL-6 or IL-18 levels and PHES score and CFF. Moreover, all patients with MHE had IL-6 levels higher than 11 ng/mL, whereas all patients without MHE had IL-6 levels lower than 11 ng/mL. Conclusions Inflammatory alterations related with IL-6 and IL-18 may contribute to MHE. Serum concentration of IL-6 and IL-18 may be useful to discriminate cirrhotic patients with and without MHE.

27 September 2011 in Hepatology
Verified
Journal Article
Open access
PDF file
Vicente FelipoVicente Felipo
Vicente Felipo
JOJuan F. Ordoño
Juan F. Ordoño
AUAmparo Urios
Amparo Urios
NMNisrin El Mlili
Nisrin El Mlili
CGCarla Giménez-Garzó
Carla Giménez-Garzó
CMCarmina Montoliu
Carmina Montoliu
Attention deficit is an early event in the cognitive impairment of patients with minimal hepatic encephalopathy (MHE). The underlying mechanisms remain unclear. Mismatch negativity (MMN) is an auditory event-related potential that reflects an attentional trigger. Patients with schizophrenia show impaired attention and cognitive function, which are reflected in altered MMN. We hypothesized that patients with MHE, similarly to those with schizophrenia, should show MMN alterations related with attention deficits. The aims of this work were to assess whether (1) MMN is altered in cirrhotic patients with MHE, compared to those without MHE, (2) MMN changes in parallel with performance in attention tests and/or MHE in a longitudinal study, and (3) MMN predicts performance in attention tests and/or in the Psychometric Hepatic Encephalopathy Score (PHES). We performed MMN analysis as well as attention and coordination tests in 34 control subjects and in 37 patients with liver cirrhosis without MHE and 23 with MHE. Patients with MHE show reduced performance in selective and sustained attention tests and in visuomotor and bimanual coordination tests. The MMN wave area was reduced in patients with MHE, but not in those without MHE. In the longitudinal study, MMN area improved in parallel with performance in attention tests and PHES in 4 patients and worsened in parallel in another 4. Logistic regression analyses showed that MMN area predicts performance in attention tests and in PHES, but not in other tests or critical flicker frequency. Receiver operating characteristic curve analyses showed that MMN area predicts attention deficits in the number connection tests A and B, Stroop tasks, and MHE, with sensitivities of 75%-90% and specificities of 76%-83%. Conclusion : MMN area is useful to diagnose attention deficits and MHE in patients with liver cirrhosis. (Hepatology 2012;)

3 July 2014 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
ITIsidro Torregrosa
Isidro Torregrosa
CMCarmina Montoliu
Carmina Montoliu
AUAmparo Urios
Amparo Urios
MAMaría Jesús Andrés-Costa
María Jesús Andrés-Costa
CGCarla Giménez-Garzó
Carla Giménez-Garzó
AMAlfonso Miguel
Alfonso Miguel

1 September 2011 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
CMCarmina Montoliu
Carmina Montoliu
Omar CauliOmar Cauli
Omar Cauli
AUAmparo Urios
Amparo Urios
NENisrin ElMlili
Nisrin ElMlili
MSMiguel A Serra
Miguel A Serra
Vicente FelipoVicente Felipo
Vicente Felipo
Between 30 and 50% of the cirrhotic patients who do not show symptoms of clinical hepatic encephalopathy (HE) present minimal hepatic encephalopathy (MHE), with mild cognitive impairment. MHE impairs the quality of life, increases the risk of suffering accidents, predicts the appearance of clinical HE, and is associated with shortened lifespan. Early detection of MHE would be very useful. The “gold standard” for MHE diagnosis is the psychometric hepatic encephalopathy score (PHES). However, it is time consuming and needs adjusting for age and educational level. It would be very useful to have some blood biomarker reflecting the presence of MHE in cirrhotic patients. The aim of this work was to identify serum molecules useful as biomarkers for MHE. We measured in 63 controls, 43 cirrhotic patients without MHE, and 44 patients with MHE, from Hospital Clinico de Valencia, serum levels of different amino acids, cyclic guanosine monophosphate (cGMP), nitrites+nitrates, and 3-nitrotyrosine. We analyzed for each parameter its diagnostic accuracy as an indicator of MHE, as assessed using the PHES. These studies supported that 3-nitro-tyrosine is a good marker for MHE. To validate its utility as a biomarker for MHE, we analyzed in a second cohort of 44 cirrhotic patients without MHE and 18 patients with MHE, from Hospital Arnau de Vilanova, serum levels of 3-nitro-tyrosine, methionine, and citrulline. Citrulline (173±17%), methionine (173±16%), and 3-nitro-tyrosine (857±92%) were increased in sera from patients with MHE when compared with those without MHE. The receiver operating characteristic (ROC) curve analysis of 3-nitro-tyrosine for the diagnosis of MHE in the first cohort showed an area under the curve (AUC) value of 0.96 (95% confidence interval 0.93–0.99). At the cutoff of 14 nM, the specificity was 93%, sensitivity 89%, and positive and negative predictive values were both 91%. When the same cutoff was applied to the second cohort, the specificity was 83% and sensitivity was 94%. The positive and negative predictive values were 70 and 97%, respectively. This pilot study, to be validated in a larger cohort, shows that determination of 3-nitro-tyrosine in serum, which is easy and not time consuming, is useful to identify patients with MHE, with good sensitivity, specificity, and positive and negative predictive values.

1 April 2000 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
AMAlicia Martı́nez
Alicia Martı́nez
AUAmparo Urios
Amparo Urios
MBManuel Blanco
Manuel Blanco